SMED — Stock Film
STOCK FILMSCENE 1/11SMED · $8.75
Stock Expert AI presents
SMED
Sharps Compliance Corp
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Sharps Compliance Corp. A quick introduction.

On the stock market since 1994, it operates in the world of heavy industry. It has 190 employees. Now — the numbers.

on the stock market since 1994
190 employees
$0 market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $17 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 17%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
65%Mailbacks
Mailbacks 65%Route-based Pickup Services 18%Unused Medications 11%Product and Service, Other 6%Third Party Treatment Services 1%
65% of all revenue comes from a single line: Mailbacks.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales are growing, year after year.

Average growth of 19% a year over the last 4 years. Red columns mark years that ended in a loss.

$38.2M
2017
$40.1M
2018
$44.3M
2019
$51.1M
2020
$76.4M
2021
Cash on hand:
$0
Total debt:
$0
The cash outweighs the debt.

If every debt were paid off today, $14.3M would still be left in the vault — a solid cushion for hard times.

Every quarter, analysts set a profit bar.
How many of the last 8 did the company clear?
4 / 8
EXPECTATIONS MET OR BEATEN
4
Aug 2020
Oct 2020
Jan 2021
Apr 2021
Aug 2021
Oct 2021
Jan 2022
May 2022
4 TIMES IN THE LAST 8 QUARTERS
A mixed scorecard.
THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 52% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
A fat but narrowing margin

The net profit margin is 17% — still a thick cushion, though costs have been eating into it lately.

2
THE BRIGHT SIDE · 2/3
Sales keep climbing

Over the last 3 years, sales grew about 24% a year on average.

3
THE BRIGHT SIDE · 3/3
Strong cash, light debt

There is $27.8M in the vault; even if every debt were paid off, $14.3M would remain.

1
THE RISKS · 1/2
Executives lean toward selling

Over the last 12 months, executives reported 25 sells against just 6 buys. Not an alarm bell by itself, but a number worth watching.

2
THE RISKS · 2/2
The stock has lost its spark

Since the drop from its peak, buyer appetite hasn’t come back.

FINALE · THE GRADE
C
0 / 100 · MoonshotScore

On our five-subject report card, SMED sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: SMED is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film